Browsing by subject "Safety profile"
Now showing items 1-1 of 1
Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer. (2017-09)Anaplastic lymphoma kinase rearrangement (ALK+) occurs in approximately 2-7% of patients with non-small cell lung cancer (NSCLC), contributing to a considerable number of patients with ALK+ NSCLC worldwide. Ceritinib is a ...